Initial characteristics of the patients according to the treatment group CHVP versus HDT
Characteristics . | CHVP . | HDT . | P . |
|---|---|---|---|
| B symptoms present, no. | 28 | 14 | .009 |
| Sex, M/F, no. | 47/33 | 38/48 | .017 |
| Histology, no. | .03 | ||
| Grade I | 40 | 28 | |
| Grade II | 38 | 50 | |
| Grade III | 2 | 8 | |
| Ann Arbor stage, no. | .1 | ||
| II | 6 | 4 | |
| III | 22 | 8 | |
| IV | 52 | 64 | |
| Performance status grade, no. | .11 | ||
| 0 | 44 | 39 | |
| 1 | 35 | 38 | |
| 2 or greater | 1 | 9 | |
| Median age, y (range) | 50 (29-61) | 51 (32-60) | .15 |
| Serum LDH greater than normal, no. | 32 | 24 | .41 |
| FLIPI, no. | .4 | ||
| Low | 23 | 26 | |
| Intermediate | 31 | 40 | |
| High | 26 | 20 | |
| Mass greater than 10 cm, no. | 28 | 25 | .77 |
Characteristics . | CHVP . | HDT . | P . |
|---|---|---|---|
| B symptoms present, no. | 28 | 14 | .009 |
| Sex, M/F, no. | 47/33 | 38/48 | .017 |
| Histology, no. | .03 | ||
| Grade I | 40 | 28 | |
| Grade II | 38 | 50 | |
| Grade III | 2 | 8 | |
| Ann Arbor stage, no. | .1 | ||
| II | 6 | 4 | |
| III | 22 | 8 | |
| IV | 52 | 64 | |
| Performance status grade, no. | .11 | ||
| 0 | 44 | 39 | |
| 1 | 35 | 38 | |
| 2 or greater | 1 | 9 | |
| Median age, y (range) | 50 (29-61) | 51 (32-60) | .15 |
| Serum LDH greater than normal, no. | 32 | 24 | .41 |
| FLIPI, no. | .4 | ||
| Low | 23 | 26 | |
| Intermediate | 31 | 40 | |
| High | 26 | 20 | |
| Mass greater than 10 cm, no. | 28 | 25 | .77 |
For CHVP, n = 80; for HDT, n = 86.
CHVP indicates cyclophosphamide, doxorubicin, etoposide, prednisone; HDT, high-dose therapy; and FLIPI, Follicular Lymphoma Prognostic Index.